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Health economics is a science to opti-
mize resource allocation. Therefore, health 
economics can only be applied when there 
are choices(1), and there are no dearth of 
choices in modern medicine. The character-
istic feature of health economics is that it 
deals both with inputs, or costs, and out-
puts, or consequences(1). In this article, 
we will be discussing the applications of 
health economics in medical research and 
clinical epidemiology with reference to 
technology assessment. 
Medical Technology and Technology 
Assessment 
All of us involved with the health care 
are keenly aware of rapid advances in vari-
ous technologies that are flooding the 
market. The word technology means drugs, 
devices, instruments and operations (2) 
used in health care. Before we can accept a 
new technology, we have to know how 
good is it and this issue is addressed by 
medical research which uses the principles 
of clinical epidemiology. We also have to 
know how much better is the new when 
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compared to the old, and this question in 
answered by health economics. Whenever 
a new technology is discovered it usually 
goes through predefined phases of assess-
ment to prove its worth. 
Phases of Technology Assessment 
Each medical technology ideally goes 
through three phases of assessment. In the 
first phase there is just an assessment of its 
technical characteristics. For example, what 
is the anti-bacterial activity of a new drug, 
or what is the sensitivity and specificity of 
a new diagnostic test, or what is the resolu-
tion of a new scanning devise, etc. In the 
second phase, the efficacy of a diagnostic 
or therapeutic technique is assessed. The 
best evidence for this comes from a ran-
domized controlled trial. However, other 
observational studies, namely case-control 
and cohort studies, can provide lesser 
quality of evidence. 
New technology that has been assessed 
on the basis of epidemiological study de-
signs will hardly ever be applied in the 
very same setting, much lesser so if it was a 
clinical trial. Therefore, in third phase, we 
assess how good this new technology will 
be in real life situation and in a different set 
of patients. We also compare the costs and 
benefits provided by the new and the old 
technologies. When there are multiple clini-
cal endpoints, we may also try to distin-
guish the effects of the old versus new on 
the quality of life. 
If new technology is better than the old, 
it may change the practicing patterns of 
physicians. But before this can happen, it is 
better to do an economic analysis to find 
what would be effect of this change to the 
payer or provider. Here, payer is usually 
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the patient and the provider may be a 
hospital. Stated differently, before a new 
technology comes into routine practice, 
it is better to assess its policy implications 
by employing the principles of health 
economics. 
Cube of Health Economics 
The basic terminologies used in health 
economics are shown in the cube in 
Fig 2(3). Three basic concepts involved in 
economic assessment are: (i) Type of analy-
sis that is performed; (ii) Types of costs and 
benefits that are included in the analysis; 
and (iii) Point of view from which the 
analysis is undertaken. This cube shows 
how these different considerations come 
together in an economic assessment. Ap-
preciating the three dimensions is the key 
to understanding the analysis as a whole. 
Three types of analysis may be per-
formed: cost identification, cost-effective-
ness and cost-benefit (4). They distinguish 
whether or not benefits are assessed in the 
analysis and how these benefits are quanti-
fied. If only the costs are assessed, it be-
comes cost identification study. If the bene-
fits are also assessed in terms of health 
points, then it is cost-effectiveness analysis. 
If all the health benefits that are provided 
are quantified in monetary terms, then it is 
called cost-benefit analysis. 
Three types of costs and benefits may 
be considered: direct, indirect and intangi-
ble. Direct costs are those that can be attrib-
uted to the change in health status, e.g., cost 
of medicines and hospitalization. Indirect 
costs are those incurred due to illness, e.g., 
loss of wages and transport costs. Intangi-
ble costs are those that cannot be measured 
in monetary terms but are equally impor-
tant. For example, response to loss of hair 
following anticancer therapy or indwelling 
catheter for continuous ambulatory peri-
toneal dialysis. 
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Finally, there are four points of view 
from which the analysis may be under-
taken: that of the patient or that of the 
provider of health care or that of the payer 
or that of the society. 
Data for Economic Analysis 
The data that goes into economic analy-
sis comes from the second phase of techno-
logy assessment, when the medical re-
search is actually done. Ideally, at this stage 
we must define our economic objectives 
and end points and collect data on relevant 
variables. For example, if we are carrying 
out a randomized trial of six monthly 
albendazole for improving nutritional sta-
tus of preschool children(5), we must anti-
cipate in advance that before this interven-
tion can have policy implications, the 
health care providers would like to know 
its cost-effectiveness. To carry out the rele-
vant cost-effectiveness analysis, in phase 
two itself, we must collect relevant cost 
data with the data on effectiveness in both 
the arms of the trial. 
Sometimes we come across two differ-
ent situations. The first situation is one 
where medical research on a new techno-
logy has already been done without the 
collection of data on appropriate economic 
variables. If we now plan to do an econo-
mic analysis, the economic data have to be 
imported from the next best available 
source. The second situation is that when 
economic analysis is done before the medi-
cal trial. Here the data on various clinical 
end points is assumed. Data on economic 
end points is derived from different surro-
gate sources. Various types of modeling 
techniques are used to then assess the tech-
nology. The primary aim of these types of 
analyses are to argue in favor or against a 
medical research trial or give a rough guide 
to the physicians on whether or not to use 
the technology, prior to the availability of 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the trial results. For example, if a new drug 
has been found to effective in the treatment 
of acquired immunodeficiency syndrome 
(AIDS), it may be unethical to withhold its 
use till the data of randomized trial is avail-
able. The data on drug efficacy can be as-
sumed and data on cost can be imported 
from other studies on AIDS patients. By 
various modeling techniques the incremen-
tal cost-effectiveness ratio of this new drug 
can be calculated. This will be of help to 
the physicians while making a decision on 
the use of new drug. Since the estimates of 
costs and sometimes effects are uncertain, 
sensitivity analysis has to be done to check 
for the robustness of the results (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Applications of Health Economics in 
Different Situations 
To clarify the applications of health 
economics in medical technology assess-
ment, we will discuss its use in the follow-
ing situations: 
1. When a new diagnostic test has been 
developed. 
2. When we want to launch a new screen- 
ing test. 
3. When we want to launch a preventive 
strategy. 
4. In resource allocation when planning a 
policy. 
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Fig. 1. Cube of health economics 
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Diagnostic Test 
Table I shows the 2x2 table for basic as-
sessment of a diagnostic test. In terms of 
cost, all four cells will have the same cost of 
testing. Cell A will have the cost of the dis-
ease, cell B will have the intangible cost of 
being told that the test is positive as well as 
direct cost of disease, if treated. Cell C will 
incur cost of delayed treatment. Those in 
cell D will have the relief from knowing 
correctly that they are not diseased. 
If the cost of delayed treatment is much 
more and the disease can be fatal, then we 
want the least number of patients in cell C, 
therefore a very sensitive test will optimize 
our resources. If the cost of wrong treat-
ment is more than correctly treating a pa-
tient, we need a small cell B and a highly 
specific test. The example here will be 
treatment for malignancy. And if the pain 
of missed as well as wrong diagnosis are 
high, that is, being either in cell B or C is 
bad, we will need a test with high sensitivi-
ty and high specificity. The example here 
will be testing for HIV. These preferences 
for a diagnostic test will only be formally 
known through technology assessments 
which uses the principles of health 
economics. 
Screening Test 
From a diagnostic test we go on to a 
screening test. The aspects of a diagnostic 
test do carry over, but the difference here is 
that the subjects are not diseased (Table II). 
The test is intended to be applied to larger 
populations. As proportion that will be 
truly diseased is small, there will be many 
false positives. Going back to the 2x2 table 
for screening test (Table II), many people 
will fall in cell B. 
The next logical question is how can we 
alter and for how much longer can we alter 
the long term outcomes of a disease by 
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detecting it early. If the available inter-
vention is not helpful it is better not do the 
screening test. The two classical examples 
are detection of asymptomatic glancoma 
and mammography in women less than 50 
years of age. In both these situations early 
detection is not of much benefit, therefore 
screening is a waste of money. It can add to 
the intangible cost of pain and misery of 
knowing the diagnosis early. Decisions in 
both the above situations have considered 
the cost of test, cost of treatment and its 
complications, long term survival as well 
as the quality of life issues. 
The example of providing benefit from 
a test is screening for hypothyroidism soon 
after birth. If the condition is detected ear-
ly, thyroid hormone supplementation can 
be given to prevent irreversible brain dam-
age. From an economist's point of view the 
question is whether we have the monetary 
resources to screen a large number of neo-
nates to provide benefit to a few. 
To give an example with numbers, we 
will use a screening test "X" for detection 
of high bilirubin levels (> 15 mg/dl) in neo- 
TABLE I-2x2 Table for Basic Assessment of 
a Diagnostic Test. 
Disease 
Test Yes         No 
Positive A B 
Negative C D 
TABLE II-2 x 2 Table for Assessment of a 
Screening Test. 
   Population 
Test Disease    No disease 
Positive A B 
Negative C D 
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nates in the first week of life. High bilirubin 
level can cause long term damage to ba-
bies. The screening test has a sensitivity of 
68.6% and specificity of 65.7% (Table III). 
The cost of test is Rs 20. The cost of hospital 
stay of mother and baby is Rs. 100. We do 
expect more of false positives and a bigger 
cell B. We see this in Table III. But what we 
have to consider is the cost of a false 
negative and false positive test. If all test 
negatives are discharged, then being a false 
negative means that the baby will be read-
mitted or the diagnosis of high serum bi-
lirubin will be missed. The consequences of 
missed diagnosis means a small risk of in-
tellectual impairment and a smaller risk of 
kernic-terus. If we are willing to take this 
risk, then we will discharge 61% of the test 
negatives. 
Treatment 
Now, let us consider a disease for which 
a new modality of treatment has been iden-
tified. And we want to know how efficient 
is this new intervention when compared to 
the old one; or, how much benefit does a 
patient get and for how much cost. Table IV 
shows the two by two table for assessment 
of interventions. New treatment will be tra-
ditionally good if (A/A+B) is greater than 
(C/C+D). In terms of health care, new 
treatment will dominate over the old one if 
it is cheaper than the old one and also cures 
more people. 
The issue of dominance is further ex-
plained in Fig. 2. Suppose we compare two 
interventions, A and B, for a common con-
dition. If A costs less than B, but A has 
TABLE III- Example of a Screening Test "X" for 
High Serum Bilirubin (≥ 15 mg/dl) 
Disease   No disease 
Test      24 82 Sensitivity: 68.6% 
Test      11 157 Specificity: 65.7% 
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more effects than B, then A dominates; and 
vice-versa for B. But what if the new treat-
ment is cheaper and cures less? Should we 
still adopt it? Here, we have to consider 
who pays and how much is the person will-
ing to pay and with how much certainity 
does the person want a cure. These ques-
tion can only be answered after economic 
assessment has compared these choices. 
To complicate the issue, the cure rates 
may be biased if the two treatment modali-
ties were not compared by randomized 
trial. Also, the outcome may not be as clear 
as "cure" and "no cure". The outcomes 
may be various degrees of clinical im-
provement or cosmetic disfigurement due 
to surgery. Thus, we now have to consider 
patient's preferences. For this we can use 
quality adjusted life years as the outcome 
of interest and our final analysis will show 
the amount of money that we are willing to 
pay for each unit of quality adjusted life 
years that we gain. 
Preventive Strategy 
Let us consider a preventive strategy. 
Usually, we launch a preventive strategy 
after we have demonstrated by medical tri-
als or literature reviews that prevention 
works, and have shown by economic as-
sessments that it is cheaper than all other 
alternatives or saves money. But once this 
has been done, prevention basically gets 
decentralized (2). It goes in the hands of 
public themselves and to adopt it is depen-
dent on their desires; for example, smoking 
TABLE IV- 2x 2 Tables for Assessment New 
Treatment Modality 
Outcome 
Cured Not cured 
New treatment A B 
Old treatment C D 
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Costs 
Effects       
A<B A>B 
A Incremental 
A > B Dominant        cost-effectiveness 
analysis 
Incremental B 
A < B        cost-effectiveness        Dominant 
analysis 
Fig. 2. Economic comparison of intervention issue 
of dominance. 
cessation, diet and aspirin for angina. Even 
the best quality of health economic assess-
ment may not convince a person to adopt a 
preventive strategy. So, thereafter, no sim-
ple assessment can calculate its incremental 
cost-effectiveness ratio in the real life situa-
tion. 
Resource Allocation 
Like with preventive strategy, economic 
assessment is needed before resource allo-
cation can be done at any level to ensure ef-
ficiency. It is also recommended before any 
program is launched and while programs 
are going on. To do such types of analysis, 
we have to identify all costs, including the 
program costs. Considerations must be 
made for long term costs and benefits and 
opportunity costs (1). 
For this, we will take the example of 
giving 6-monthly albendazole to preschool 
children (5). Suppose this means that 10 
million children each year have to be treat-
ed and assuming that the annual treatment 
cost is Rs. 4, then the intervention cost to 
treat 10 million children will be Rs. 40 
million. Now Rs. 40 million was just the 
cost of intervention. To this has to be added 
the program cost of drug delivery. Based 
on the results of the randomized trial (5), 
the effectiveness will be an extra 1-2 kilo- 
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grams weight gain with intervention. 
Weight gain with intervention will result in 
a reduction in proportion of underweight 
children and this may also result in a 
reduction in mortality related to or con-
founded by malnutrition. 
Going back to the question with which 
we started: will we do this intervention? 
The question is as yet unanswered, because 
we have also to know from where will this 
money come. Stated differently, the oppor-
tunity cost (1) of implementing six 
monthly albendazole for preschool 
children has to be considered. If we fund 
this program, the money will have to be 
taken away from somewhere else. Now we 
have to consider the consequences of 
taking away money from that place. All 
these sets of issues are dealt with at the 
level of policy planning. AH the principles 
of clinical epidemiology and health 
economics are employed for this purpose. 
Conclusion 
Health economics is very meaningful 
for a country like India where medical 
resources are scarce. Economic assessment 
is a part of good quality medical research. 
Both together are required for technology 
assessment. Therefore, while planning re-
search, we must decide our economic aims 
and objectives lay down our hypothesis, 
calculate sample size for economic out-
comes and define variables for economic 
data collection. In an ideal research world, 
clinical and economic data are collected 
simultaneously. Therefore, clinical epi-
demiology and health economics are an 
inseparable part of medical research. Good 
quality epidemiological and cost data, 
when combined, give the most reliable esti-
mates of cost-effectiveness. To keep in pace 
with the advances going on, we have to 
keep re-analyzing older technologies as the 
newer ones keep coming in. 
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